Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabozantinib in Radioiodine-Refractory Differentiated Thyroid Cancer After Prior VEGFR Therapy
2024-516478-31-00Phase 3Authorised
- Sponsor
- Exelixis, Inc.
- Start
- Oct 2024
- Modality
- Small Molecules
- Countries
- 9
01
Overview
Phase 3, randomised, double-blind trial in well-differentiated thyroid cancer (WDTC) comparing CABOMETYX with Placebo (2 arms). Primary endpoints: Progression-free survival and Objective response rate. Planned start Oct 2024; status: authorised.
02
Drugs
cabozantinib
03
Conditions
well-differentiated thyroid cancer (WDTC)
Beyond the preview
Go deeper on 2024-516478-31-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516478-31-00.